logo
Share SHARE
FONT-SIZE Plus   Neg

Genzyme's Gaucher Drug Shows Positive Results In Follow Up Data Of Phase 2 Trial

Genzyme Corp., a unit of Sanofi-Aventis (SNY,SNYNF.PK), Wednesday said that a four-year follow-up data from a phase 2 trial for its investigational oral drug 'eliglustat tartrate' for Gaucher disease, showed further improvements across all endpoints.

Sustained or further improvements were observed across all endpoints, including markers of bone disease, at the four-year timepoint, Genzyme said in a statement.

Gaucher disease (pronounced Go-shay) is an inherited genetic disorder, in which patients lack the normal form of glucocerebrosidase, or GCD enzyme that breaks down specific fat molecules. The lack of this enzyme results in the accumulation of fat in liver, spleen and bone marrow. The disease affects about 1 in 100,000 persons in the general population.

Genzyme previously reported that the 52-week phase 2 trial of eliglustat tartrate had met its primary composite endpoint. Patients have continued to receive eliglustat tartrate in the extension portion of the study for over four years. The data from patients on eliglustat tartrate after four years indicate continued or stabilized improvements across all endpoints.

The composite endpoint is clinically meaningful response in at least two of three endpoints i.e. improvements in spleen size, hemoglobin and platelet levels in individual patients.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The best companies make employees feel comfortable, safe and valued at their workplace. Corporate culture develops organically over time from the cumulative traits of the people hired by the company. It is a combination of values, goals and vision of an organization that dictates the way people work.... Starbucks will close all its 379 Teavana stores over the coming year, with the coffee giant saying that the stores have been "persistently underperforming." The move will impact about 3,300 employees. The company made the announcement while reporting its third-quarter financial results on Thursday. Wal-Mart Stores has disappointed Nintendo fans after it cancelled pre-orders for the Super Nintendo Entertainment System - Classic Edition, a standalone mini Super Nintendo with pre-loaded games. The console is slated to be launched later this fall.
comments powered by Disqus
Follow RTT